Loading clinical trials...
Loading clinical trials...
A Phase II, Open-label, Single-arm, Non-randomized, Multi-center Study to Evaluate the Efficacy of Oral TKI258 as Second-line Therapy in Patients With Either FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer
Conditions
Interventions
TKI258
Locations
45
United States
University of South Alabama / Mitchell Cancer Institute Univ South Alabama
Mobile, Alabama, United States
St. Jude Heritage Medical Group St Jude
Fullerton, California, United States
USC/Kenneth Norris Comprehensive Cancer Center USC 2
Los Angeles, California, United States
Cedars Sinai Medical Center TKI258A2211 (SC)
Los Angeles, California, United States
University of California at Los Angeles UCLA 3
Los Angeles, California, United States
Rocky Mountain Cancer Centers Dept. of Rocky Mountain Cancer
Greenwood Village, Colorado, United States
Start Date
November 1, 2011
Primary Completion Date
March 1, 2014
Completion Date
March 1, 2014
Last Updated
May 20, 2015
NCT05489211
NCT04657068
NCT07029399
NCT04585750
NCT06975293
NCT07166094
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions